Authors in this area focused on increasing diversity in clinical trials through patient-first payment options and trial design.
Below are the most read diversity, equity, and inclusion (DE&I) articles featured on Applied Clinical Trials in 2023.
1. Increasing Clinical Trial Diversity Through Patient-First Payment Options
Patient-first trial design, based around the tenets of adaptability and personalization, has emerged as a key solution to increase diversity and improve trial outcomes for all. There is an increasing focus on the need to flex trial designs to meet the needs of participants, whether they are logistical, financial, or educational.
However, uptake of new technologies that offer patient optionality is far from universal, in part due to the industry’s desire to stay in its comfort zone. This hesitation is particularly apparent in clinical trial payments.
Read the full article here.
2. 12 Questions We Need to Answer to Achieve Diversity in Clinical Research
DE&I has, deservedly, become a hot topic in clinical research. Numerous organizations are developing methodologies, products and programs. If “let a thousand flowers bloom” is the best way to achieve diversity, we are certainly on track. However, we should be able to minimize duplicative efforts and accelerate learning through collaboration. The best place to start this collaboration is to develop consensus answers to the following 12 fundamental questions.
Read the full article here.
3. The Impact of Trial Design on Interest by Race and Ethnicity
The life sciences industry is collectively recommitted to better addressing challenges to diversity and inclusion in clinical trials, especially among traditionally underserved populations. What we know is that there is no singular formula to effectively resolve this longstanding issue. As such, clinical trial sponsors, their contract research organization (CRO) partners, and other industry stakeholders are recognizing the importance of approaching each trial program with a deliberate focus on diversity goals during trial design and planning activities.
Read the full article here.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.